Evidence map›Paper›PMID 34558396›Full record

ArticleInternational psychogeriatrics2021

Is bigger better? Towards a mechanistic understanding of neuropsychiatric symptoms in Alzheimer's disease.

Milap A Nowrangi, Paul B Rosenberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International psychogeriatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Milap A NowrangiDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI PAUL F WORLEY · 2020 to 2026
$29.3M
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)R01AG050515 · NIA · JOHNS HOPKINS UNIVERSITY · PI FORESTER, BRENT PETER, ROSENBERG, PAUL B · 2016 to 2021
$5.5M
Circadian rhythm disturbance and agitation in Alzheimer's diseaseR01AG054771 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B, WU, MARK N · 2017 to 2021
$3.4M
Neural Network Connectivity of Financial Capacity in Mild Cognitive ImpairmentK23AG055626 · NIA · JOHNS HOPKINS UNIVERSITY · PI NOWRANGI, MILAP A · 2017 to 2022
$1.1M
NIA NIH HHS K23 AG055626NIA NIH HHS P30 AG066507NIA NIH HHS R01 AG050515NIA NIH HHS R01 AG054771
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseHumansNeuropsychological Tests

Identifiers

PMID34558396
PMCPMC8805711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.